Document Detail

Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution.
MedLine Citation:
PMID:  12407649     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Icodextrin is a new peritoneal dialysis fluid, with maltose polymers providing the osmotic drive, that may extend time on peritoneal dialysis in situations in which use of conventional glucose-based peritoneal dialysis fluid (Dianeal) has led to loss of ultrafiltration. Although cutaneous reactions have been reported, we report a new phenomenon of aseptic peritonitis that has arisen in our unit associated with icodextrin use. METHODS: Icodextrin was first introduced in our unit in 1997 and was used extensively beginning in late 1999. From a combination of an observational study of 141 patients in our unit in whom icodextrin was used over 3.5 years and our unit 2000 and 2001 peritonitis audits, we identified an increase in the incidence of culture-negative peritonitis (CNP). RESULTS: The rate in 2000 of 12.3% rose to 17% in 2001, but this increase was seen only in patients on icodextrin (Percentage changes 2000 audit > 2001 audit: icodextrin patients, 14%--31% increase; Dianeal alone, 12%--10% increase; P < 0.05). Six patients were affected in the period 2000 to 2001 out of a total of 141 patients exposed to icodextrin (4.3%). Two index cases of relapsing CNP responded after withdrawal of the icodextrin. We then adopted a protocol of cessation and rechallenge with icodextrin when dealing with CNP, which successfully confirmed the phenomenon and led to resolution of relapsing CNP after icodextrin withdrawal. All these patients had been on icodextrin for some time, and none had had an immediate reaction or any skin reaction. Eosinophils were reported in the peritoneal effluent from two patients. All patients continued Dianeal without further CNP episodes. CONCLUSION: Icodextrin use carries the risk of CNP, and we suggest a cessation and rechallenge protocol in all patients on icodextrin who have CNP.
Robert MacGinley; Katrina Cooney; Geraldine Alexander; SueMien Cohen; David J A Goldsmith
Related Documents :
15627789 - Continuous ambulatory peritoneal dialysis in familial mediterranean fever amyloidosis p...
18226129 - Clinical significance of pregnancies with circumvallate placenta.
11174409 - Treatment of porphyria cutanea tarda with phlebotomy in a patient on peritoneal dialysis.
11239039 - Comparison of infectious complications in peritoneal dialysis patients using either a t...
15042549 - Hyperphosphatemia in chinese peritoneal dialysis patients with and without residual kid...
16228819 - Enterocolitis associated with cocaine use.
15961709 - Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the ...
11050029 - Dyskinesias and motor fluctuations in parkinson's disease. a community-based study.
16382379 - Plasma levels of nt-pro-bnp in patients with atrial fibrillation before and after elect...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  40     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2002 Nov 
Date Detail:
Created Date:  2002-10-30     Completed Date:  2002-12-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1030-5     Citation Subset:  IM    
Copyright Information:
Copyright 2002 by the National Kidney Foundation, Inc.
Renal Unit, Guy's Hospital and St Thomas's Hospital, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Glucans / adverse effects*,  contraindications,  therapeutic use
Glucose / adverse effects*,  contraindications,  therapeutic use
Hemodialysis Solutions / adverse effects,  contraindications,  therapeutic use
Middle Aged
Peritoneal Dialysis / adverse effects,  methods*
Peritonitis / chemically induced*,  microbiology
Ultrafiltration / adverse effects,  methods
Reg. No./Substance:
0/Glucans; 0/Hemodialysis Solutions; 0/icodextrin; 50-99-7/Glucose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ACE inhibitors and survival of hemodialysis patients.
Next Document:  Derived equations are not precise enough to predict the adequacy of creatinine clearance in peritone...